Erenumab

Drug Profile

Erenumab

Alternative Names: Aimovig; AMG 334; Anti-CGRP-receptor-monoclonal-antibody-Amgen; Calcitonin gene-related peptide receptor antagonist monoclonal antibody - Amgen; CGRP receptor antagonist monoclonal antibody - Amgen

Latest Information Update: 21 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Amgen
  • Class Antimigraines; Monoclonal antibodies
  • Mechanism of Action Calcitonin gene-related peptide antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Migraine
  • Phase II Angina pectoris
  • No development reported Hot flashes

Most Recent Events

  • 20 Jul 2017 FDA assigns PDUFA action date of 17/05/2018 for erenumab for Migraine (Prevention)
  • 20 Jul 2017 The US FDA accepts BLA for erenumab for Migraine for review
  • 21 Jun 2017 The European Medicines Agency (EMA) accepts marketing authorisation application (MAA) for erenumab for Migraine for review
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top